Bora Pharmaceuticals CoTPE:6472 +1.74%87 PEG Ratio is 0.25 as of Jul. 06, 2026, which is 14% below its 10-year median of 0.29. GuruFocus rates TPE:6472 with a GF Score™ of 87/100 and a GF Value™ of NT$717.57 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 349 Drug Manufacturers companies, Bora Pharmaceuticals Co ranks better than 95.99% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Bora Pharmaceuticals Co's PEG Ratio or its related term are showing as below:
TPE:6472'
s PEG Ratio Range Over the Past 10 Years
Min: 0.12 Med: 0.29 Max: 0.79
Current: 0.25
During the past 13 years, Bora Pharmaceuticals Co's highest PEG Ratio was 0.79. The lowest was 0.12. And the median was 0.29.
TPE:6472's PEG Ratio is ranked better than 95.99% of 349
companies
in the Drug Manufacturers industry
Industry Median: 1.75
vs TPE:6472: 0.25
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Bora Pharmaceuticals Co (TPE:6472) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bora Pharmaceuticals Co PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Bora Pharmaceuticals Co's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Bora Pharmaceuticals Co (TPE:6472) has a PEG Ratio of 0.25 as of Jul. 06, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Bora Pharmaceuticals Co and its competitors. This is 14% below median its historical median of 0.29. Over the past decade, Bora Pharmaceuticals Co's PEG Ratio has ranged from 0.12 to 0.79. According to the industry distribution chart, Bora Pharmaceuticals Co ranks #14 out of 349 companies in the Drug Manufacturers industry, placing it in the top 4%.
Is Bora Pharmaceuticals Co's PEG Ratio too high?
Bora Pharmaceuticals Co's current PEG Ratio of 0.25 is 14% below median its 10-year median of 0.29. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 0.79. The Drug Manufacturers industry median PEG Ratio is 1.75. Bora Pharmaceuticals Co's value of 0.25 is 85.7% below this industry median. Based on the distribution chart, Bora Pharmaceuticals Co ranks #14 out of 349 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bora Pharmaceuticals Co has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bora Pharmaceuticals Co ranks #14 out of 349 companies for PEG Ratio. This places Bora Pharmaceuticals Co in the top 4% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 1.75. Bora Pharmaceuticals Co's value of 0.25 is 85.7% below this benchmark. Historically, Bora Pharmaceuticals Co's own PEG Ratio has ranged from 0.12 to 0.79 over the past decade. While the company's 10-year median is 0.29 vs. the industry median of 1.75, Bora Pharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.75, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bora Pharmaceuticals Co's current PEG Ratio of 0.25 is 85.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Bora Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bora Pharmaceuticals Co's current PEG Ratio is 0.25, which is 14% below median its own 10-year median of 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$717.57, compared to a current price of NT$439.50 — trading 38.8% below its estimated fair value. The current PEG Ratio is 0.25, which is 14% below median its 10-year median of 0.29 and 85.7% below the Drug Manufacturers industry median of 1.75. Bora Pharmaceuticals Co's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current PEG Ratio is 0.25 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$439.50 is trading 38.8% below its estimated GF Value™ of NT$717.57.
GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for TPE:6472:
PEG Ratio: 0.25 (14% below median its 10-year median of 0.29)
GF Value™: NT$717.57 vs. price of NT$439.50 (38.8% below fair value)
Industry Position: 85.7% below the Drug Manufacturers median (#14 of 349)
No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
87GF Score
Get the complete analysis for TPE:6472
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6472 has been successfully added to your 
